PULMAG Grzegorz Gasior Marzena Kociolek s.c.

At PULMAG Grzegorz Gasior Marzena Kociolek s.c. in Sosnowiec, much of the clinical trial activity focuses on respiratory tract diseases, especially asthma. Studies are looking at how new and existing treatments can better control symptoms, reduce flare-ups, and lower the need for long-term steroid use.

• Severe and inadequately controlled asthma
• Oral corticosteroid dependent asthma
• Moderate-to-severe asthma
• Mild to moderate asthma

This research is aimed at testing new therapies and comparing treatment options to improve day-to-day breathing control and overall disease management.

A major area of investigation is chronic obstructive pulmonary disease (COPD), with trials examining whether different inhaled treatments can improve lung function and reduce exacerbations. The studies also explore how well patients respond to new formulations and combination therapies in routine disease control.

• Chronic obstructive pulmonary disease (COPD)
• Moderate to Severe Chronic Obstructive Pulmonary Disease
• Chronic obstructive pulmonary disease and chronic bronchitis

The goal is to evaluate treatment effectiveness, support better symptom control, and help prevent worsening of the disease.

The site is also involved in research on interstitial lung disease, including idiopathic pulmonary fibrosis and related fibrotic conditions. These trials are focused on finding therapies that may slow disease progression, preserve lung capacity, and improve patient outcomes over time.

• Idiopathic pulmonary fibrosis
• Systemic sclerosis-associated interstitial lung disease

This line of research supports the development of new options for a serious group of lung diseases with limited treatment choices.

Clinical trials at this site also cover bronchiectasis and respiratory syncytial virus (RSV), alongside broader immune system diseases and immune system phenomena. These studies aim to understand how new treatments may reduce infection-related symptoms, support airway health, and improve control of chronic respiratory inflammation.

• Bronchiectasis
• Respiratory syncytial virus (RSV)
• Immune system diseases
• Immune system phenomena

The research reflects an interest in both infection-related respiratory illness and inflammation-driven disease, with an emphasis on testing innovative therapies and improving care options.